← Analyst Upside
AU · rank #20 · 2026-09-07
AMLX
NASDAQ · $3.80B (USD)
SignalSell
verdict · CAUTION
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.494 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.11 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 0 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.159 |
| Analyst upside Consensus target $42.36 | +24.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +93.08% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.57 |
| Gross margin TTM | +13901.8% |
| 52w high | $41.14 |
| Market cap (USD) | $3.80B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing avexitide, a potential first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia.
Rationale
Positive topline Phase 3 LUCIDITY trial results for avexitide validate the model's strong momentum signal and six recent analyst price target raises.
Material risks
- 1Extreme pipeline concentration on a single clinical asset, avexitide, makes the entire investment thesis vulnerable to any future FDA regulatory delays or rejection.
- 2Substantial near-term shareholder dilution and pricing pressure from the proposed $350 million underwritten public offering of common stock.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.
OpenAI
Caution
Claude
Caution
Gemini
Proceed